Ramy Sedhom, MD, of Penn Medicine Princeton Health discusses blending palliative care with psycho-oncology to treat patient distress in oncology care.
|Articles|March 4, 2011
- December 2010
- Volume 4
- Issue 6
Bone Loss Drugs Increase Stroke Risk in Patients With Cancer
Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk
Advertisement
Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk for atrial fibrillation and stroke. According to a study published online in the Journal of Clinical Oncology, the absolute risk for these patients within 6 years of starting bisphosphonate treatment was approximately 8% for all supraventricular tachycardia events and 4% for stroke.
Articles in this issue
over 15 years ago
Net Guides: Melanomaover 15 years ago
Net Guides: Bone Metastasesover 15 years ago
Yoga for Cancer Careover 15 years ago
FDA Updatesover 15 years ago
The Future of Nursingover 15 years ago
Net Guides: Liver Cancerover 15 years ago
Net Guides: Carcinoma of Unknown Primary Orginover 15 years ago
Tools to Help Patients Navigate Their Treatment Pathover 15 years ago
John Theurer Cancer Center Opens New Comprehensive Facilityalmost 16 years ago
Oncology Community Facing Severe Drug ShortagesAdvertisement
Related to this article
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
At WCLC 2026, Kaitlyn Gregory details key oncology nursing insights into exercise, caregiver stress, screening models, and APP-led supportive care.
For Gynecologic Cancer Awareness Month, Dr. Eleonora Teplinsky outlines emerging treatment toxicities, patient advocacy, and health equity.
FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
Gigi Jameel, APRN, discusses supportive care interventions, ADT toxicity management, and team collaboration in prostate cancer care.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
2
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
3
Recognizing and Evaluating Diarrhea in Metastatic Triple-Negative Breast Cancer
4
Patient Education for Gastrointestinal Toxicity in Metastatic Triple-Negative Breast Cancer
5